Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ASK: "THE LAST DON" OF MOMENTUM TRADES -- Ignore unavailable to you. Want to Upgrade?

To: MoneyMade who wrote (7357)	2/24/1999 6:47:00 AM
From: Mr Metals	Respond to of 15987

WOW...IMCL...WOW Industry Analysis Feb 22, 1999 Biotech/Drugs:ImClone's 3-Pronged Attack on Cancer Bob Hirschfeld An aging population will increasingly turn to new remedies to keep a life-threatening menace at bay. Cancer is often quickly fatal, and causes 25% of all deaths. Yet, oncology drugs account for only 5% of drug sales, according to Barron's. Analysts expect drug outlays to expand rapidly if new therapies can extend patients' lives. Lehman's biotechnology team sees oncology drugs "on the cusp of a boom," and forecasts $8 billion in cancer drugs sales by 2000, with growth driven by new therapies, expedited drug approvals, and an aging population. On the prospect of finding cures for cancer, analyst Jim McCamant of the Medical Technology Stock Letter sounds extremely hopeful. "We expect the treatments already being tested …to cut the death rate from cancer in half over the next five to ten years. In the process, the market will grow rapidly, and a number of companies will make a lot of money," he said. There are many ways to fight cancer. Among the most popular are tumor vaccines to prevent cancer cells from spreading and using antibodies to arrest cancer cell growth. Another approach is anti-angiogenesis, in which a drug short-circuits the growth of tumor-forming blood vessels. Amazingly, ImClone (NASDAQ:IMCL - news) is one company that is exploring all three cancer treatment approaches. ImClone's Best Medicine: C225 ImClone's lead product is called C225 -- a drug that inhibits the growth of skin cancer cells and has been used with radiation treatments in Phase I/II trials in treating head and neck cancer patients. The trials produced outstanding results: 14 of the 16 head and neck cancer patients treated with C225 plus radiation showed a 100% tumor regression, as compared with historical rates of 30%-40% for radiation alone. Following these successful trials, ImClone's timetable for deploying C225 was pushed forward. A one-year Phase III enrollment is slated to begin in the first quarter 1999, and then a one-year follow-up. Product approval is likely by mid-2001, with a product launch by 2002. ImClone's C225 could easily become a billion dollar drug, according to the Medical Technology Stock Letter's McCamant . The drug targets patients with high levels of skin cancer cell growth or EGF (Epidermal Growth Factor), which is characteristic of more than one-third of all cancer tumors. Though McCamant says initial approval for C225 is likely to be for head and neck cancer, ImClone is also assembling data on both renal cell (kidney or surrounding area) and pancreatic cancers. There are about 80,000 patients with high levels of cancer cell growth in these three disease categories in the U.S. alone, and none are well-treated under current therapies. According to McCamant, a dearth of treatment makes a rapid market penetration rate of about 50% more likely. Add to that a per-patient revenue estimate of $10,000 per year, and McCamant estimates the C225 market at $400 million. That assessment does not include the potential C225 customers that are among the 130,000 patients with lung cancer and a similar number with colorectal cancer who also express high levels of cancer cell growth. While the size of the cancer market is huge, stock-pickers will also be excited by current valuations. A useful approach, says McCamant, is the "multiple of future sales" metric. Though four times revenue is realistic and conservative, it may be too conservative given that some companies with new products now sell at closer to ten times revenue. A good example is IDEC Pharmaceuticals (NASDAQ:IDPH - news) , which has gleaned a market cap of $900 million based on its share of half the profits of Rituxan, a $200 million revenue-per-year drug. Calculating that multiple for ImClone, McCamant says he "finds it hard to believe" sales of C225 will be less than $200 million by 2002, and possibly as high as $500 million. Using the midpoint multiple of 7.5 times revenue, the analyst sees a range of between $1.5 billion and $3.75 billion in ImClone's market capitalization. That nets to a share price range of $60 - $150, a dramatic improvement over the current price of $10 per share. In December, ImClone signed an agreement with Merck KG, granting that company license to market C225 outside North America. The deal brought ImClone milestone payments in exchange for premium price equity -- $30 million upfront, and a $30 million credit line to build out the manufacturing facility. It must be wonderful having such a confident, blue-chip and deep-pocketed partner. Merck said it expects C225 "to go on sale in three years." Other analysts are also sanguine about ImClone's prospects. Wole Fayemi of Cruttenden Roth recently reiterated his Strong Buy and set a 1999 price target of $16 per share. Fayemi cited ImClone's pivotal trial of C225 and the new hire of Ron Martell, who had helped Genentech commercialize Herceptin, the highly successful breast cancer antibody. Fayemi is also enthusiastic about BEC-2, ImClone's cancer therapy vaccine, which is now in the enrollment stage of a multinational Phase III trial; Fayemi expects ImClone's vaccine product to reach the market by 2003. Bottom Line: We are excited about ImClone's diverse approach to finding not one, but potentially three treatments for cancer. We are also heartened by its recent Merck partnership, and the enormous potential of C225. We recommend investors consider the purchase of ImClone shares as part of a diversified biotech portfolio. For more in-house professional stock analysis and commentary, visit us at Individual Investor Online. MM

To: MoneyMade who wrote (7357)	2/24/1999 8:12:00 AM
From: Kevin McKenzie	Respond to of 15987

MoneyMade, You mean TMRK right, not TRMK. TRMK is Trustmark, a bank with 71M shares out and 43M shares in float. Just correcting so others don't throw their money in Trustmark thinking it is Trimark.

To: MoneyMade who wrote (7357)	2/24/1999 9:14:00 AM
From: EZ ED	Read Replies (1) \| Respond to of 15987

FILM-NEWS Hollywood Productions, Inc. Announces 104% Net Income Increase for Fourth Quarter 1998 Nasdaq Symbols: Common Stock - FILM Warrants - FILMW February 23, 1999 08:59 PM NEW YORK, Feb. 23 /PRNewswire/ -- HOLLYWOOD PRODUCTIONS, INC. FILM announced its net income results for the fourth quarter, 1998. Hollywood Productions was pleased to announce an 104% increase in net income in the quarter ending December 31, 1998, over the previous years quarter. Hollywood Productions' net income figure for the three month period ending December 31, 1998 amounted to approximately $436,612, or $0.16 per share based on a weighted average number of shares of 2,686,944 as compared to a net income of $214,327, or $0.11 per share based on a weighted average number of shares of 2,040,463 in the quarter ending December 31, 1997. This represented an improvement of $222,285 or $0.05 of net income per share All figures are based on unaudited results. Hollywood also announced that it has taken a 25% stake in the OTC company Play Co Toys and Entertainment Corp. ("PLCO") PLCO . Play Co. Toys is a toy retailer with 25 stores located in southern California, Arizona, Illinois, Michigan, Nevada and Texas. The Company operates under the Play Co. Toys, Toys International and Toy Co. tradenames. Play Co. Toys specializes in offering educational, specialty, collectible, and traditional toys. Play Co announced record results for the nine-month period ended December 31, 1998. The Company posted sales of $27,171,662, a $9,403,629, or 52.9% increase over its comparable 1997 nine-month sales of $17,768,033. Play Co posted a profit before interest, taxes, depreciation and amortization (EBITDA) of $2,359,935 in the nine-month period ended December 1998 compared to EBITDA of $254,771 in the nine-month period ended December 1997. This represented an EBITDA improvement of $2,105,164, or 826.3%. Additionally, Hollywood's core business, feature film production is moving ahead on schedule. Its second feature film, "MACHIAVELLI RISES," newly completed and fresh from very favorable audience responses at the non- competitive, Brussell's International Film Festival, will be "suited-up" for several upcoming festivals here in the states. Also, the company is actively reviewing new screenplays and budgets and examining the feasibility of entering into new co-ventures in the near future. In addition, we are looking at the new advances in digital for projects which are not intended for theatrical (made for TV, cable, video, pay per view and other media not associated with large screen projection) distribution. Several of this year's Sundance films were shot on inexpensive film equipment (still many thousands of dollars but less than 35mm film equipment) with excellent results. Statements contained in this press release which are not historical facts may be considered forward looking information with respect to plans, projections, or future performance of Hollywood Productions, Inc. as defined under the Private Securities Litigation Reform Act of 1995. These forward- looking statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. SOURCE Hollywood Productions, Inc.

To: MoneyMade who wrote (7357)	2/24/1999 9:24:00 AM
From: DablocTrader	Read Replies (2) \| Respond to of 15987

CHECK THIS OUT: NEWS ON CSYS!! Screaming Buy!!! Real company, real earnings, real product! Shares Outstanding: 6,270,000 Active Float: Only 2 Mil PATENT RECEIVED! News after market close yesterday: biz.yahoo.com DO YOU HAVE A TEEN AGE DAUGHTER WITH ACNE Like mine? Folks, MY OWN DAUGHTER had me order these for her from their highly effective infomercial two months ago!!! Here is a partial Business Summary: (Full Report:http://www.wallstreetresearch.net/csys/report.html "Circle Systems, Inc. (based in Ft.Lauderdale, FL) through its wholly owned subsidiaries, Circle Laboratories, Inc., and Winner's Circle Incentive Program, Inc., manufactures and markets facial cleansing products and operates a school-based promotion. The mission of Circle Laboratories is to provide active people, particularly acne prone teens and young adults with a line of facial care products that are portable, disposable and convenient for use throughout the day. The mission of Winner's Circle Incentive Program is to operate a school-based promotion that provides an incentive for students in grades K-12 to earn good grades on their report cards. FACIAL CARE AND ACNE TREATMENT IS A $615 MILLION MARKET! According to Hydra International, Ltd., 85% of all teens and 35% of all adults struggle with some form of acne during their lives. Today's increased emphasis on health and cleanliness creates a demand for facial cleansing products that is growing rapidly. A study by Information Resources Inc. shows that Acne Treatments were $246.2 million and Facial Cleansers $369.3 million respectively for a total in excess of $615 million through July 1997. Currently, Stridex, Oxy, Clearasil, Neutrogena, Noxzema, and Clean & Clear are the six national brands which account for 86% of the acne treatment and facial cleansers market. UNIQUE AND COMPETITIVE ADVANTAGE OF POCKET SCRUBZ: 1.The primary focus of Circle Laboratories is the medicated acne pad market. Acne pads have been widely known and marketed for two decades – in plastic jars, saturated with cleansing solution. These products are not conveniently portable and tend to leak, not good for purses and/or backpacks. Circle Labs has developed the world's first portable acne pads and is the first and only company marketing facial cleansing products in convenient, portable, single use packets! This portability feature sets Pocket Scrubz (trade marked) apart from all other acne pads on the market and therefore offers a distinct and very competitive advantage. Additionally, the packets are very competitively priced on an individual basis and in different size boxes. This unique nature of the packet lends itself to quick market acceptance and success. Currently, all competing acne pad brands are available exclusively in plastic, screw-top jars, which presents three problems for consumers that Pocket Scrubz was created in order to solve." MUCH MORE! Read the full report, wallstreetresearch.net dbl